Obstetrics, gynecology, andrology, sexual and reproductive health

Breast diseases

PubMed Free Full Text

Breast cancer treatment: monoclonal antibodies

Australia

• Medical Services Advisory Committee
  • Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab [2017]

Austria

• Oncologist
  • Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer [2012]

Colombia

• Revista de Salud Pública
  • ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country [2014]

Europe

• ESMO Open
  • Flexible care in breast cancer [2021]

Germany

• BMC Cancer
  • Trastuzumab in advanced breast cancer - a decade of experience in Germany [2014]

• Breast Care
  • Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007 [2011]

Hong Kong

• Hong Kong Medical Journal
  • Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong [2023]

India

• JCO Global Oncology
  • Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India [2020]

International

• Critical Reviews in Oncology/Hematology
  • Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis [2023]

• Current Breast Cancer Reports
  • Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer [2017]

• PLoS ONE
  • The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis [2022]

Iran

• PharmacoEconomics
  • Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [2018]

Italy

• Oncologist
  • Cardiovascular risk after adjuvant trastuzumab in early breast cancer: an Italian population-based cohort study [2020]

Japan

• Breast Cancer Research and Treatment
  • A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study [2019]

• Molecular and Clinical Oncology
  • Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan [2015]

Netherlands

• Breast Cancer Research and Treatment
  • Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry [2021]

• Oncotarget
  • Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium [2017]

New Zealand

• PLoS Medicine
  • Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis [2016]

Norway

• Norwegian Institute of Public Health
  • Health Economic Analysis of Bevacizumab + Paclitaxel Versus Paclitaxel Alone as First-Line Treatment for Metastatic Breast Cancer [2009]

Philippines

• BMC Health Services Research
  • Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines [2019]

Singapore

• Annals Academy of Medicine Singapore
  • Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer [2015]

United Kingdom

• National Institute for Health and Care Excellence
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [2023]
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [2021]
  • Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [2020]
  • Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [2019]
  • Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer [2018]
  • Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [2017]
  • Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [2016]
  • Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab [2013]
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer [2012]
  • Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer [2011]

United States

• American Journal of Managed Care
  • Integrating Trastuzumab Biosimilars and HER2-Directed Therapies into HER2-Positive Breast Cancer Management [2020]

• JNCCN
  • Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer [2018]

• Journal of Clinical Oncology
  • Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter [2016]

{Related topics}

• Guidelines
  • Breast cancer treatment